Pages that link to "Q36476690"
Jump to navigation
Jump to search
The following pages link to Towards a vaccine for Cryptococcus neoformans: principles and caveats. (Q36476690):
Displaying 28 items.
- New insights on the development of fungal vaccines: from immunity to recent challenges (Q26776056) (← links)
- Host immunity to Cryptococcus neoformans (Q26823438) (← links)
- Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations (Q30479935) (← links)
- Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components (Q30483673) (← links)
- The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. (Q33912345) (← links)
- The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies (Q34099803) (← links)
- Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans (Q34680995) (← links)
- Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation (Q34720443) (← links)
- Vaccines for invasive fungal infections (Q35161720) (← links)
- Role of Sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development (Q35938253) (← links)
- Glucosylceramide Administration as a Vaccination Strategy in Mouse Models of Cryptococcosis (Q35991081) (← links)
- Recent progress in vaccines against fungal diseases (Q36179629) (← links)
- Extracellular polysaccharides from Ascomycota and Basidiomycota: production conditions, biochemical characteristics, and biological properties. (Q36210222) (← links)
- Strain-related differences in antibody-mediated changes in gene expression are associated with differences in capsule and location of binding (Q36350251) (← links)
- Immunomodulators as an antimicrobial tool (Q36576318) (← links)
- Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan (Q36844895) (← links)
- HIV and co-infections (Q36970184) (← links)
- Animal models: an important tool in mycology (Q37008692) (← links)
- Fungal vaccines: real progress from real challenges (Q37067893) (← links)
- Induction of Protective Immunity to Cryptococcal Infection in Mice by a Heat-Killed, Chitosan-Deficient Strain of Cryptococcus neoformans. (Q37123421) (← links)
- Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease (Q37140093) (← links)
- Vaccines to prevent systemic mycoses: holy grails meet translational realities (Q37390781) (← links)
- Mechanisms of cryptococcal virulence and persistence (Q37781066) (← links)
- An insight into the antifungal pipeline: selected new molecules and beyond. (Q37781273) (← links)
- Immune modulators as adjuncts for the prevention and treatment of invasive fungal infections (Q38067451) (← links)
- Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. (Q41913077) (← links)
- Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences (Q43029434) (← links)
- Carbohydrate Moieties as Vaccine Candidates: meeting summary (Q51874502) (← links)